Moderna (MRNA) Payables (2017 - 2026)

Moderna (MRNA) has reported Payables for 10 consecutive years, with $167.0 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Payables fell 4.57% year-over-year to $167.0 million in Q2 2026; TTM through Jun 2026 was $167.0 million, a 4.57% decrease from a year earlier, with the FY2025 full-year figure at $317.0 million, down 21.73% from the prior year.
• Payables was $167.0 million for Q2 2026 at Moderna, up from $161.0 million in the prior quarter.
• Over five years, Payables peaked at $520.0 million in Q4 2023 and troughed at $161.0 million in Q1 2026.
• A 5-year average of $303.5 million and a median of $294.5 million in 2023 frame the typical range for Payables.
• Across the five-year window, Payables surged 2387.5% in 2022 and tumbled 52.96% in 2024, its largest moves.
• Over 5 years, Payables stood at $487.0 million in 2022, then climbed by 6.78% to $520.0 million in 2023, then fell by 22.12% to $405.0 million in 2024, then slipped by 21.73% to $317.0 million in 2025, then slumped by 47.32% to $167.0 million in 2026.
• The last three Payables figures came in at $167.0 million (Q2 2026), $161.0 million (Q1 2026), and $317.0 million (Q4 2025), per Business Quant data.